DB 959 pharmacokinetics and tolerability in volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2011
At a glance
- Drugs T3D 959 (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 28 Jun 2011 The primary endpoint of tolerability was met, according to a DARA BioSciences media release.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 21 Apr 2011 Results from this trial will be presented at the 71st American Diabetes Association Scientific Sessions, according to a DARA BioSciences media release.